Coherus Oncology Inc is a commercial-stage oncology company focused on developing and commercializing proprietary immuno-oncology medicines. The company markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor approved for nasopharyngeal carcinoma, and is advancing two mid-stage clinical candidates targeting liver, head and neck, and colorectal cancers.
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.